Mark A. Meltz - 01 Dec 2022 Form 4 Insider Report for Kinnate Biopharma Inc.

Role
COO General Counsel Secretary
Signature
Mark A. Meltz
Issuer symbol
N/A
Transactions as of
01 Dec 2022
Net transactions value
-$4,193
Form type
4
Filing time
02 Dec 2022, 19:00:11 UTC
Previous filing
02 Sep 2022
Next filing
14 Feb 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction KNTE Common Stock Tax liability $4,193 -541 -1.9% $7.75 27,924 01 Dec 2022 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Includes 23,438 shares represented by restricted stock units ("RSUs"). Each RSU represents the Reporting Person's right to receive one share of Common Stock of the Issuer. A portion of the RSUs vest each quarter, subject to the Reporting Person's continued service as of each vesting date.